electroCore FY2028 EPS Forecast Increased by HC Wainwright

electroCore, Inc. (NASDAQ:ECOR) – HC Wainwright boosted their FY2028 earnings per share (EPS) estimates for electroCore in a research report issued to clients and investors on Thursday, March 13th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $2.25 for the year, up from their previous forecast of $2.24. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for electroCore’s current full-year earnings is ($1.49) per share. HC Wainwright also issued estimates for electroCore’s FY2029 earnings at $3.07 EPS.

Separately, LADENBURG THALM/SH SH cut their price objective on electroCore from $28.00 to $26.00 and set a “buy” rating for the company in a research report on Thursday.

electroCore Trading Down 10.4 %

Shares of ECOR opened at $8.56 on Friday. The firm has a market cap of $56.98 million, a P/E ratio of -4.68 and a beta of 0.24. electroCore has a 12 month low of $5.32 and a 12 month high of $19.49. The stock’s 50 day moving average is $15.84 and its two-hundred day moving average is $12.26.

Institutional Trading of electroCore

Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in shares of electroCore by 31,250.0% in the fourth quarter. JPMorgan Chase & Co. now owns 3,762 shares of the company’s stock worth $61,000 after acquiring an additional 3,750 shares during the last quarter. DnB Asset Management AS acquired a new stake in shares of electroCore in the fourth quarter worth approximately $180,000. NewEdge Advisors LLC acquired a new stake in shares of electroCore in the fourth quarter worth approximately $274,000. Jane Street Group LLC acquired a new stake in shares of electroCore in the fourth quarter worth approximately $278,000. Finally, Marshall Wace LLP acquired a new stake in shares of electroCore in the fourth quarter worth approximately $438,000. 26.74% of the stock is owned by institutional investors and hedge funds.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.